CN101647813A - Bionic enzymatic hydrolysate for animal medicaments and application thereof - Google Patents
Bionic enzymatic hydrolysate for animal medicaments and application thereof Download PDFInfo
- Publication number
- CN101647813A CN101647813A CN200810118147A CN200810118147A CN101647813A CN 101647813 A CN101647813 A CN 101647813A CN 200810118147 A CN200810118147 A CN 200810118147A CN 200810118147 A CN200810118147 A CN 200810118147A CN 101647813 A CN101647813 A CN 101647813A
- Authority
- CN
- China
- Prior art keywords
- animal
- enzymolysis
- enzymatic hydrolysate
- medicaments
- add
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses bionic enzymatic hydrolysate for animal medicaments and application in antiviral medicaments, and belongs to the field of Chinese medicaments. The bionic enzymatic hydrolysateadopts the technical scheme that: a bionic enzymolysis method is adopted; the animal medicaments are taken; and after water is added in the animal medicaments so as to form homogenate, under proper conditions, the heat preserving enzymolysis is carried out firstly by pepsin, and then the heat preserving enzymolysis is carried out by pancreatin or trypsase. Compared with the product in the prior art, the obtained bionic enzymatic hydrolysate has stronger biological activity, and has the better therapeutic effect in antiviral aspect.
Description
Technical field
The present invention relates to a kind of bionic enzymatic hydrolysate of animal drugs and the application in antiviral drugs thereof, belong to the field of Chinese medicines.
Background technology
Animal drugs is as Chinese medicine, and clinical practice is very extensive, after usually adopting crude drug to pulverize on the mode of being used as medicine, directly taking, water is carried or alcohol extraction or water extract-alcohol precipitation after take, its extracting method of taking is tradition relatively.Studies show that now micromolecular oligopeptides material and aminoacid are easy to by little intestinal absorption, and macromolecular protide is difficult in small intestinal be absorbed.Traditional former powder is directly taken, high molecular weight protein in the former medicated powder, have only on a small quantity and decompose through gastrointestinal in vivo, become micromolecular oligopeptide and be absorbed, because the fineness of pulverizing medicinal materials, the variation of gastrointestinal tract pH cause not finishing of hydrolysis, what effective ingredient was absorbed and used lacks, and causes the waste curative effect of a large amount of medical materials to reduce greatly.Water is carried, the extraction process of water extract-alcohol precipitation makes most of insoluble entry, the albumen of alcohol is removed by filtration, causes a large amount of medical material wastes, and curative effect reduces equally greatly.
Along with people go deep into the understanding of animal drugs, the single albumen that has the people to extract from animal drugs is made preparation, but makes oral formulations, owing to through gastrointestinal tract, fallen its loss of activity easily by gastric enzyme, pancreatin enzymolysis; If make injection,, there is certain potential safety hazard because macromolecular protide causes immunogenicity easily.
Use the enzymatic isolation method hydrolyzed animal protein, the biologically active peptide that acquisition has certain physiologically active is the focus of studying both at home and abroad at present.Because the position of different enzyme hydrolysiss is different, the enzymatic hydrolysate that obtains also differs widely, position such as the main enzymolysis of pepsin is a phenylalanine, the peptide bond that tyrosine and leucine are formed, the position of the main enzymolysis of trypsin is an arginine, the peptide bond that basic amino acids such as lysine are formed, use single pepsin, pancreatin or other protease come enzymolysis, albumen is effectively absorbed, like this with regard to a kind of new enzyme solution of exigence---in animal or human's body biological evolution process, be proved, determined curative effect, the bionic enzymatic method of the digestion process of simulation human body, with the easier absorption of effective ingredient in the animal drugs, safer utilization makes full use of crude drug simultaneously more.
Summary of the invention
First purpose of the present invention is to provide a kind of more effective, safe bionic enzymatic hydrolysate for animal medicaments, and this bionic enzymatic hydrolysate is that animal drugs obtains through bionic enzymatic.
Second purpose provides the application of this bionic enzymatic hydrolysate aspect virus drugs such as preparation treatment anti-HBV, HCV, HDV, HPV, HSV.
Specifically:
The present invention relates generally to a kind of bionic enzymatic hydrolysate for animal medicaments, and this bionic enzymatic hydrolysate prepares by the following method:
Get animal drugs, add water homogenate, regulate pH to 1.0～3.0, add pepsin, regulate pH to 7.5～8.5, add pancreatin or trypsin in 40～50 ℃ of insulation enzymolysis 2～8 hours in 35～45 ℃ of insulation enzymolysis 0.5～4 hour.
Further preferred, this extract prepares by the following method:
Get animal drugs, add water homogenate, regulate pH to 1.5～2.5, the pepsin that adds animal dose 0.5～5% is incubated enzymolysis 1～3 hour in 35～45 ℃, re-adjustment pH to 7.5～8.5, add the pancreatin of animal dose 0.5～5% or trypsin in 40～50 ℃ of insulation enzymolysis 3～6 hours, promptly.
Preferred again, this enzymatic hydrolysate prepares by the following method:
Get animal drugs, add water homogenate, regulate pH to 2.0, the pepsin that adds animal dose 1～2% is in 40 ℃ of insulation enzymolysis 1～3 hour, and re-adjustment pH to 8.0 adds the pancreatin of animal dose 1～2% or trypsin in 50 ℃ of insulation enzymolysis 3～6 hours, promptly.
The inventor after the animal drugs medical material adds water homogenate, can be heated to 80～100 ℃ in advance through experiment sieving, be incubated 15～30 minutes, puts that to be chilled to enzymolysis temperature required again, presses above operation enzymolysis, and its effect is stronger.Carry out enzymolysis by technical solution of the present invention, when pepsic enzyme activity reaches 1200U/g, tryptic enzyme activity reaches 2500U/mg, and the casein conversion power of pancreatin reaches at 25.0 o'clock, and effect is comparatively abundant; Enzyme activity is high more, and enzymolysis speed is fast more, effect is good more.By method of the present invention operation, the anticoagulation of animal drugs, invigorate blood circulation, antiinflammatory, antiviral isoreactivity strengthen greatly, is better than the former powder of animal drugs, water extract, alcohol extract and water extract-alcohol precipitation liquid commonly used in the past.
Animal drugs among the present invention is selected from Hirudo, Pheretima, Eupolyphaga Seu Steleophaga, Scorpio, Scolopendra, Periostracum Cicadae, Bombyx Batryticatus, Mylabris, Cornu Cervi, Cornu Saigae Tataricae, Stichopus japonicus, Gecko etc., and it all has antiviral efficacy, and has solid clinical practice basis.
Those skilled in the art can cooperate bionic enzymatic hydrolysate of the present invention with suitable pharmaceutic adjuvant easily, are prepared into injection, freeze dried powder, oral formulations and external preparation etc., as:
A, with the direct spray drying of enzymolysis solution, add an amount of conventional adjuvant such as starch, lactose, microcrystalline Cellulose, carboxymethyl starch sodium etc. and make preparations such as capsule, granule, tablet.
B, with enzymolysis solution be heated to 85 ℃ kill enzyme after, filter, filtrate is divided and is got the following solution of molecular cut off 5kD with the ultrafilter membrane ultrafiltration, can add isoosmotic adjusting agent, pH regulator agent, antiseptic etc. and make injection; Also can add lyophilizing such as mannitol, lactose and make lyophilized injectable powder.
C, enzymolysis solution is filtered, filtrate is with the ultrafilter membrane ultrafiltration, the solution that molecular cut off 10kD is following, or filtrate directly adds conventional pharmaceutic adjuvants such as carbomer, chitosan, makes preparations such as gel, Wet-dressing agent, spray.
Bionic enzymatic hydrolysate for animal medicaments provided by the invention can use separately, also can unite use, that is: in active constituents of medicine, can have only this product with the other drug composition, can also be the mixture of itself and other drug, reach the purpose of partner treatment, auxiliary treatment.
Bionic enzymatic hydrolysate for animal medicaments among the present invention can be used for the treatment of diseases such as various condyloma acuminatum, hepatitis B, hepatitis C, hepatitis D, hepatocarcinoma, cervical cancer, various herpess at its antiviral effect.
Beneficial effect
For further checking product of the present invention is with respect to the progressive effect of prior art, the inventor has carried out the contrast experiment of animal pharmacodynamics, and " bionic enzymatic group " in the experiment is the animal drugs enzymatic hydrolysate that makes by technical solution of the present invention.
The drug effect comparative test (Eupolyphaga Seu Steleophaga) of test one, resisting HBV virus effect
1, medicine and reagent
The preparation of confession test agent is the enzymolysis group not: get Eupolyphaga Seu Steleophaga medical material fine powder (80 order) 50g, add 10 times of amount normal saline, homogenate 30 minutes stirs evenly, and gets 1/5 amount, and microporous filter membrane (0.45 μ m) filters, promptly;
Pepsin enzymolysis group: get 1/5 homogenate, add 1% pepsin of Eupolyphaga Seu Steleophaga medical material amount, regulate pH to 2.0 simultaneously, temperature is 40 ℃ ± 2 ℃, and enzymolysis 4h is stirred in insulation simultaneously, and 85 ℃ of insulation 20min are put coldly, and microporous filter membrane (0.45 μ m) filters, promptly;
The trypsin digestion group: get 1/5 homogenate, add 1% trypsin of Eupolyphaga Seu Steleophaga medical material amount, regulate pH to 8.0 simultaneously, temperature is 50 ℃ ± 2 ℃, and enzymolysis 4h is stirred in insulation simultaneously, and 85 ℃ of insulation 20min are put coldly, and microporous filter membrane (0.45 μ m) filters, promptly;
Pancreatin enzymolysis group: get 1/5 homogenate, add 1% pancreatin of Eupolyphaga Seu Steleophaga medical material amount, regulate pH to 8.0 simultaneously, temperature is 50 ℃ ± 2 ℃, and enzymolysis 4h is stirred in insulation simultaneously, and 85 ℃ of insulation 20min are put coldly, and microporous filter membrane (0.45 μ m) filters, promptly;
Bionic enzymatic group: get 1/5 homogenate, add 1% pepsin of Eupolyphaga Seu Steleophaga medical material amount, regulate pH to 2.0 simultaneously, temperature is 40 ℃ ± 2 ℃, enzymolysis 4h is stirred in insulation simultaneously, transfers pH to 8.0 then, adds 1% trypsin of Eupolyphaga Seu Steleophaga medical material amount, temperature is 50 ℃ ± 2 ℃, enzymolysis 4h is stirred in insulation simultaneously, and 85 ℃ of insulation 20min are put cold, microporous filter membrane (0.45 μ m) filters, promptly;
Hyclone; DMEM culture medium (Gibco company product); The HBeAg detection kit; The human liver cancer cell cell strain HepG of HBV-DNA clone transfection
2-2.2.15.
2, test method
The human liver cancer cell HepG of HBV-DNA clone transfection
2-2.2.15 cell culture is in the DMEM culture fluid that contains 10% hyclone and two anti-(100U/mL penicillin and 100 μ g/mL streptomycins), in 37 ℃, 5%CO
2Cultivate under the condition.The take the logarithm cancerous cell of trophophase is diluted to 5 * 10 with the DMEM culture fluid that contains 10% hyclone
7/ mL single cell suspension is inoculated in 96 well culture plates, every hole 100 μ L, and abandoning supernatant behind the adhere-wall culture 24h adds the different volumes medicine, and sample dissolves the mother solution that is mixed with 1mg/mL with 3% dimethyl sulfoxine, and adding DMEM culture fluid to final volume is 200 μ L.Parallel 6 holes of each concentration, matched group adds isopyknic DMEM culture fluid.Draw culture plate supernatant 5 μ L, press HBeAg detectable cassette method and detect the antigenic absorbance of e (A) value, be calculated as follows cell proliferation inhibition rate.
Cell inhibitory rate=(the A value of the A value/control cells of 1-dosing cell) * 100%
3, the concrete result of the test of result of the test sees the following form.
Table 1 couple HepG
2-2.2.15 cell inhibiting rate is table as a result
| Group | Suppression ratio (%) |
| Enzymolysis group not | ??56.31* |
| Pepsin enzymolysis group | ??63.42* |
| The trypsin digestion group | ??67.67* |
| Pancreatin enzymolysis group | ??69.69* |
| The bionic enzymatic group | ??75.37** |
Annotate: compare * P＜0.05, * * P＜0.01 with matched group.
Above-mentioned result of the test shows, bionic enzymatic hydrolysate has stronger anti-HBV effect, with do not add matched group that medicine only adds equal-volume DMEM culture fluid relatively, drug level at 10 μ g/mL demonstrates significant difference, effect than other single enzyme enzymatic hydrolysate is strong, points out bionic enzymatic hydrolysate of the present invention to have resisting HBV virus effect preferably.
The drug effect comparative test (Mylabris) of test two, anti-HPV virus function
1, medicine and reagent
The preparation of confession test agent is the enzymolysis group not: get Mylabris medical material fine powder (80 order) 50g, add 10 times of amount normal saline, homogenate 30 minutes stirs evenly, and gets 1/5 amount, and microporous filter membrane (0.45 μ m) filters, promptly;
Pepsin enzymolysis group: get 1/5 homogenate, add 1% pepsin of Mylabris medical material amount, regulate pH to 2.0 simultaneously, temperature is 40 ℃ ± 2 ℃, and enzymolysis 4h is stirred in insulation simultaneously, and 85 ℃ of insulation 20min are put coldly, and microporous filter membrane (0.45 μ m) filters, promptly;
The trypsin digestion group: get 1/5 homogenate, add 1% trypsin of Mylabris medical material amount, regulate pH to 8.0 simultaneously, temperature is 50 ℃ ± 2 ℃, and enzymolysis 4h is stirred in insulation simultaneously, and 85 ℃ of insulation 20min are put coldly, and microporous filter membrane (0.45 μ m) filters, promptly;
Pancreatin enzymolysis group: get 1/5 homogenate, add 1% pancreatin of Mylabris medical material amount, regulate pH to 8.0 simultaneously, temperature is 50 ℃ ± 2 ℃, and enzymolysis 4h is stirred in insulation simultaneously, and 85 ℃ of insulation 20min are put coldly, and microporous filter membrane (0.45 μ m) filters, promptly;
Bionic enzymatic group: get 1/5 homogenate, add 1% pepsin of Mylabris medical material amount, regulate pH to 2.0 simultaneously, temperature is 40 ℃ ± 2 ℃, enzymolysis 4h is stirred in insulation simultaneously, transfers pH to 8.0 then, adds 1% trypsin of Mylabris medical material amount, temperature is 50 ℃ ± 2 ℃, enzymolysis 4h is stirred in insulation simultaneously, and 85 ℃ of insulation 20min are put cold, microporous filter membrane (0.45 μ m) filters, promptly;
Specimen is picked up from department of dermatologry outpatient service CA patient, is accredited as the HPV6/11 type through quantitative fluorescent PCR, under aseptic condition, specimen is shredded, and grinds the CA suspension that 3 μ g/ml are made in homogenate.
The FQ-PCR detection kit; Full-automatic real-time fluorescence quantitative PCR instrument.
2, test method
Get CA suspension 100 μ l in the 1ml centrifuge tube, totally 5 groups, add above-mentioned sample solution 100 μ l respectively, jolting is even, cultivates in 37 ℃ of incubators, respectively at acting on wart body 1,3,7, carries out the test of HPV-DNA quantitative amplification.
From calorstat, take out through the CA of medicine effect suspension 50 μ l, add equal-volume DNA extraction liquid mixing, boiling water bath 10min, the centrifugal 5min of 10000r/min gets supernatant 2 μ l as the HPV-DNA amplification template.
Each group is got one of HPV-PCR reaction tube respectively, adds the sample after handling, the standard substance (1 * 10 of variable concentrations respectively
3, 1 * 10
4, 1 * 10
5, 1 * 10
6, 1 * 10
7) each 2 μ l of regulating YIN and YANG quality-control product, the centrifugal 1min of 6000r/min puts into each reaction tube the reactive tank of PCR instrument.Cycling condition: 93 ℃ of degeneration 2min, 93 ℃ of 5s then, 57 ℃, 40s circulates 40 times, after reaction finishes, automatic record data of computer software and analysis result.
3, the concrete result of the test of result of the test sees the following form.
Table 2 pair HPV virus function as a result table (n=3) (copy/ml)
Above-mentioned result of the test shows, the result＜50 viruses are destroyed or be killed, and its DNA cloning is suppressed.Results suggest bionic enzymatic hydrolysate of the present invention has anti-preferably HPV virus function.
Test three, test 3: to the clinical observation test of 102 routine genital herpess
Clinical data
Observe genital herpes case 102 examples, male 56 examples, women 46 examples, 23～50 years old age, average 32 years old.The women does not comprise the pregnant person of merging, is divided into experimental group and matched group at random, experimental group 63 examples, matched group 39 examples.Age distribution between two groups, M-F, local patholoic change and disease time are learned the check no significant difference by statistics.
Supply test agent: get Scolopendra medical material 50g, add 10 times of amount normal saline, homogenate 30 minutes, stir evenly, add 1% pepsin of Scolopendra medical material amount, regulate pH to 2.0 simultaneously, temperature is 40 ℃ ± 2 ℃, enzymolysis 4h is stirred in insulation simultaneously, transfer pH to 8.0 then, add 1% trypsin of Scolopendra medical material amount, temperature is 50 ℃ ± 2 ℃, enzymolysis 4h is stirred in insulation simultaneously, 85 ℃ of insulation 20min are put coldly, and filtrate is with the ultrafilter membrane ultrafiltration, divide and get the following solution of molecular cut off 10kD, add carbomer, swollen 12 hours transfers PH to increase viscosity, mixing is made gel.At least outward smear 5 times every day.
Contrast medicine: oral acyclovir slice, each 0.2g, every day 5 times.
Followed up a case by regular visits to after the healing 4 months, and checked relapse rate.
Observed result sees the following form:
Annotate: p＜0.05
Through last table as can be seen, bionic enzymatic hydrolysate of the present invention has anti-preferably HSV virus function.
The specific embodiment
Below further specify the present invention by specific embodiment, but following examples only are used to the present invention is described without limits to the present invention.
Embodiment 1
Get Pheretima 200g, be ground into fine powder, add 10 times of water gaging homogenate, regulate pH to 2.0,2% the pepsin that adds the Pheretima amount is regulated pH to 8.0 in 40 ℃ of insulation enzymolysis 2 hours, and 2% the pancreatin that adds the Pheretima amount was in 50 ℃ of insulation enzymolysis 5 hours, spray drying, add an amount of starch, granulate drying, granulate is loaded capsule.
Embodiment 2
Get Scorpio 500g, be ground into fine powder, add 8 times of water gaging homogenate, regulate pH to 2.6,1% the pepsin that adds the Scorpio amount is regulated pH to 7.5 in 37 ℃ of insulation enzymolysis 3 hours, and 1% the trypsin that adds the Scorpio amount was in 40 ℃ of insulation enzymolysis 6 hours, spray drying, add an amount of microcrystalline Cellulose, granulate drying, granulate, compacting are in flakes.
Embodiment 3
Water intaking Cornu Bovis seu Bubali 500g, be ground into fine powder, add 15 times of water gaging homogenate, regulate pH to 3.0,5% the pepsin that adds the Cornu Bubali amount was in 40 ℃ of insulation enzymolysis 2 hours, regulate pH to 8.5,5% the trypsin that adds the Cornu Bubali amount is heated to 85 ℃ of insulations 15 minutes in 45 ℃ of insulation enzymolysis 5 hours, filter, filtrate is divided and is got the following solution of molecular cut off 5kD with the ultrafilter membrane ultrafiltration, makes injection.
Embodiment 4
Get Eupolyphaga Seu Steleophaga 500g, be ground into fine powder, add 15 times of water gaging homogenate, regulate pH to 1.5,0.5% the pepsin that adds the Eupolyphaga Seu Steleophaga amount is regulated pH to 8.0 in 40 ℃ of insulation enzymolysis 1 hour, 1.5% the trypsin that adds the Eupolyphaga Seu Steleophaga amount was in 50 ℃ of insulation enzymolysis 3 hours, be heated to 95 ℃ of insulations 30 minutes, filter, filtrate is with the ultrafilter membrane ultrafiltration, divide and get the following solution of molecular cut off 5kD, add mannitol, lyophilized injectable powder is made in lyophilization.
Embodiment 5
Get Bombyx Batryticatus 500g, Mylabris 200g is ground into fine powder, add 15 times of water gaging homogenate, regulate pH to 2.5,4% the pepsin that adds the medical material amount is regulated pH to 8.5 in 40 ℃ of insulation enzymolysis 2 hours, 5% the trypsin that adds the medical material amount was in 45 ℃ of insulation enzymolysis 6 hours, be heated to 85 ℃ of insulations 15 minutes, filter, filtrate is with the ultrafilter membrane ultrafiltration, divide and get the following solution of molecular cut off 5kD, make spray.
Embodiment 6
Get Periostracum Cicadae 500g, be ground into fine powder, add 10 times of water gaging homogenate, regulate pH to 2.0,2% the pepsin that adds the Periostracum Cicadae amount is regulated pH to 8.0 in 40 ℃ of insulation enzymolysis 2.5 hours, and 2% the pancreatin that adds the Periostracum Cicadae amount was in 50 ℃ of insulation enzymolysis 5 hours, spray drying, add an amount of starch, granulate drying, granulate is loaded capsule.
Embodiment 7
Get Scorpio 500g, be ground into fine powder, add 12 times of water gaging homogenate, regulate pH to 2.5,2.5% the pepsin that adds the Scorpio amount is regulated pH to 8.0 in 39 ℃ of insulation enzymolysis 2.5 hours, and 3% the trypsin that adds the Scorpio amount was in 40 ℃ of insulation enzymolysis 6 hours, spray drying, add an amount of microcrystalline Cellulose, granulate drying, granulate, compacting are in flakes.
Embodiment 8
Get Mylabris 500g, be ground into fine powder, add 15 times of water gaging homogenate, regulate pH to 2.0,2.5% the pepsin that adds the Mylabris amount is regulated pH to 8.5 in 40 ℃ of insulation enzymolysis 3 hours, and 2.5% the pancreatin that adds the Mylabris amount was in 50 ℃ of insulation enzymolysis 6 hours, spray drying, add an amount of Icing Sugar and dextrin, granulate drying, granulate is made granule.
Embodiment 9
Get Scorpio 250g, Scolopendra 100g, add 15 times of water gaging homogenate, regulate pH to 2.0,1% the pepsin that adds total dose is regulated pH to 8.0 in 40 ℃ of insulation enzymolysis 2 hours, and 1% the pancreatin that adds total dose was in 50 ℃ of insulation enzymolysis 4 hours, be heated to 85 ℃ of insulations 15 minutes, filter, filtrate is with the ultrafilter membrane ultrafiltration, divide and get the following solution of molecular cut off 10kD, add carbomer, swollen 12 hours transfers PH to increase viscosity, mixing is made gel.
Embodiment 10
Get embodiment 9 obtained gel treatment genital herpes 73 examples.Among the 73 routine patients, fully recover 62 (84.93%), produce effects 8 examples (10.96%), effective 1 example (1.37%), invalid 2 examples (2.74%), total effective rate 97.26% as a result.
Embodiment 11
Get embodiment 5 obtained spray treatment condyloma acuminatum 89 examples.Among the 89 routine patients, fully recover 74 (83.15%), produce effects 7 examples (7.87%), effective 5 examples (5.62%), invalid 3 examples (3.37%), total effective rate 96.63% as a result.
Embodiment 12
Get embodiment 1 obtained capsule treatment cervical cancer 21 example.Among the 21 routine patients, fully recover 16 (76.19%), produce effects 3 examples (14.29%), effective 1 example (4.76%), invalid 1 example (4.76%), total effective rate 95.24% as a result.
Claims (10)
1, a kind of bionic enzymatic hydrolysate of animal drugs, it is characterized in that this product prepares by the following method: get animal drugs, add water homogenate, regulate pH to 1.0～3.0, add pepsin and be incubated enzymolysis 0.5～4 hour in 35～45 ℃, re-adjustment pH to 7.5～8.5 add pancreatin or trypsin in 40～50 ℃ of insulation enzymolysis 2～8 hours, promptly.
2, bionic enzymatic hydrolysate for animal medicaments according to claim 1, it is characterized in that this product prepares by the following method: get animal drugs, add water homogenate, regulate pH to 1.5～2.5, the pepsin that adds animal dose 0.5%～5% is incubated enzymolysis 1～3 hour in 35～45 ℃, re-adjustment pH to 7.5～8.5 add the pancreatin of animal dose 0.5%～5% or trypsin in 40～50 ℃ of insulation enzymolysis 3～6 hours, promptly.
3, bionic enzymatic hydrolysate for animal medicaments according to claim 2, it is characterized in that this product prepares by the following method: get animal drugs, add water homogenate, regulate pH to 2.0, the pepsin that adds animal dose 1%～2% is incubated enzymolysis 1～3 hour in 40 ℃, re-adjustment pH to 8.0 adds the pancreatin of animal dose 1%～2% or trypsin in 50 ℃ of insulation enzymolysis 3～6 hours, promptly.
4, according to arbitrary described bionic enzymatic hydrolysate for animal medicaments in the claim 1 to 3, it is characterized in that with animal drugs add be heated to earlier after the water homogenate 80～100 ℃ and be incubated 15～30 minutes after, put again and be chilled to the temperature required enzymolysis that carries out.
5, according to arbitrary described bionic enzymatic hydrolysate for animal medicaments in the claim 1 to 3, it is characterized in that used pepsic enzyme activity is not less than 1200U/g, tryptic enzyme activity is not less than 2500U/mg, and the casein conversion power of pancreatin is not less than 25.0.
6,, it is characterized in that described animal drugs is at least a in Hirudo, Pheretima, Eupolyphaga Seu Steleophaga, Scorpio, Scolopendra, Periostracum Cicadae, Bombyx Batryticatus, Mylabris, Cornu Bubali, Cornu Cervi, Stichopus japonicus, the Gecko according to arbitrary described bionic enzymatic hydrolysate for animal medicaments in the claim 1 to 5.
7, according to arbitrary described bionic enzymatic hydrolysate for animal medicaments in the claim 1 to 6, it is characterized in that being added into conventional pharmaceutic adjuvant and make injection, freeze dried powder, oral formulations and external preparation.
8, arbitrary described bionic enzymatic hydrolysate for animal medicaments is used for the treatment of application in the anti-HPV virus drugs in preparation in the claim 1 to 6.
9, arbitrary described bionic enzymatic hydrolysate for animal medicaments is used for the treatment of application in anti-HBV, HCV, the HDV virus drugs in preparation in the claim 1 to 6.
10, arbitrary described bionic enzymatic hydrolysate for animal medicaments is used for the treatment of application in the anti-HSV virus drugs in preparation in the claim 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810118147A CN101647813A (en) | 2008-08-13 | 2008-08-13 | Bionic enzymatic hydrolysate for animal medicaments and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810118147A CN101647813A (en) | 2008-08-13 | 2008-08-13 | Bionic enzymatic hydrolysate for animal medicaments and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101647813A true CN101647813A (en) | 2010-02-17 |
Family
ID=41670209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810118147A Pending CN101647813A (en) | 2008-08-13 | 2008-08-13 | Bionic enzymatic hydrolysate for animal medicaments and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101647813A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552329A (en) * | 2010-12-14 | 2012-07-11 | 吴克 | Medicine film for resisting virus |
| CN104055800A (en) * | 2013-03-23 | 2014-09-24 | 河北以岭医药研究院有限公司 | Ground beetle protease enzymolytic product and application thereof |
| CN104886336A (en) * | 2015-06-15 | 2015-09-09 | 安徽金豪生态农业科技有限公司 | Extraction method of earthworm protein power |
| CN105395611A (en) * | 2015-12-10 | 2016-03-16 | 刘力旗 | A medicine for external application for treating viral and immunological diseases and a preparing method thereof |
| CN111297786A (en) * | 2020-03-20 | 2020-06-19 | 扬州扬大联环药业基因工程有限公司 | Method for extracting active small molecules from sheep embryos in large scale |
-
2008
- 2008-08-13 CN CN200810118147A patent/CN101647813A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 刘健敏等: "海参酶法水解的工艺研究", 《中国食品工业》 * |
| 黄开华等: "胰蛋白酶酶解鹿血条件的优化", 《湖北农业科学》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552329A (en) * | 2010-12-14 | 2012-07-11 | 吴克 | Medicine film for resisting virus |
| CN104055800A (en) * | 2013-03-23 | 2014-09-24 | 河北以岭医药研究院有限公司 | Ground beetle protease enzymolytic product and application thereof |
| CN104886336A (en) * | 2015-06-15 | 2015-09-09 | 安徽金豪生态农业科技有限公司 | Extraction method of earthworm protein power |
| CN105395611A (en) * | 2015-12-10 | 2016-03-16 | 刘力旗 | A medicine for external application for treating viral and immunological diseases and a preparing method thereof |
| CN111297786A (en) * | 2020-03-20 | 2020-06-19 | 扬州扬大联环药业基因工程有限公司 | Method for extracting active small molecules from sheep embryos in large scale |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100464756C (en) | Application of fucoidan in the preparation of medicine and health-care products for preventing and treating neurodegenerative diseases | |
| CN104844723A (en) | Preparation method and application of dendrobium officinale extract | |
| CN101647811A (en) | Bionic enzymatic product of animal medicament and application thereof | |
| CN1207005C (en) | Rabbit skin containing bioactive substance and its use | |
| CN108785328A (en) | Prevent or treat method and the bear gall powder used of entity tumor and hematological system tumor | |
| CN108743622A (en) | Immunity of organisms and muscle power are improved using bear gall powder and alleviate the method for organism fatigue | |
| CN101647822A (en) | Bionic enzymatic hydrolysate for ground beeltle and application thereof | |
| CN101647813A (en) | Bionic enzymatic hydrolysate for animal medicaments and application thereof | |
| CN108743621A (en) | The bear gall powder and preparation method of ice crystal state | |
| CN108635375A (en) | Prevent or treats hepatopathy and liver fibrosis and improve the bear gall powder and purposes of liver function | |
| CN102743739B (en) | Preparation method for blattodea polypeptide substance, and medical use of blattodea polypeptide substance in anti-herpesvirus | |
| CN108578433A (en) | For preventing or treating gall stone cholecystitis and improve the bear gall powder of gallbladder function | |
| CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
| KR20160064966A (en) | Medical composition and applications thereof used for secondary chemotherapy drugs | |
| CN108653332A (en) | Inhibition thrombosis and platelet aggregation and the bear gall powder and purposes for preventing cerebral ischemia | |
| CN112322681B (en) | Traditional Chinese medicine maggot active peptide and preparation method and application thereof | |
| CN102068475B (en) | Application and blood-sugar lowering effective part of trapa acornis nakano shell as well as extraction method of blood-sugar lowering effective part | |
| CN109589400B (en) | Composition with neuroprotective effect | |
| CN110856744B (en) | New application of dendrobe polypeptide | |
| CN112516183B (en) | Preparation method and application of extract with repair effect on trauma | |
| TW202237158A (en) | Use of rhodococcus ruber cell wall skeleton in the treatment of radiation related disease | |
| CN113521262A (en) | Lysozyme preparation with anti-inflammatory effect | |
| JPS6236009B2 (en) | ||
| CN101948439A (en) | Extraction method and application to medicine of active alkaloid compounds in cervus nippon temminck | |
| CN110292621A (en) | The antitoxin antibacterial complexing agent of anti-HPV viruse infection and its preparation method of phase inversion gel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20100217 |